The relationship between plasma androgens (dehydroepiandrosterone sulfate and testosterone) and coronary arteriosclerosis in men: The lower the androgens, the higher the coronary score of arteriosclerosis

References

• Kaplan G A, Goldberg D E, Everson S A, Cohen R D, Salonen R, Tuomilehto J, et al. Perceived health status and morbidity and mortality: evidence from the Kuopio ischaemic heart disease risk factor study. Int J Epidemiol 1996; 25: 259–65
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995; 273: 199–208
   PubMed Web of Science ®Google Scholar
• Wolf P H, Madans J H, Finucane F F, Higgins M. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489–94
   PubMed Web of Science ®Google Scholar
• Godsland B A, Wynn V, Crook D, Miller NE. Sex plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467–503
   PubMed Web of Science ®Google Scholar
• Morrison J A, deGroot I, Edwards B K, Kelly KA. Plasma cholesterol and triglyceride levels in 6775 school children aged 6–17. Metabolism 1977; 26: 1199–204
   PubMedGoogle Scholar
• Laskarzewski P M, Morrison J A, Gutai J, Orchard T. High and low density lipoprotein cholesterols in adolescent boys. Relationship with endogenous testosterone, estradiol and quetelet index. Metabolism 1983; 32: 262–7
   PubMedGoogle Scholar
• Nordy A, Aakvaag A, Thelle D. Sex hormones and high density lipoproteins in healthy males. Atherosclerosis 1979; 34: 431–6
   PubMedGoogle Scholar
• Yarnell J WG, Beswick A D, Sweetnam PM. Endogenous sex hormones and ischemic heart diseases in men. Arterioscler Thromb 1993; 13: 517–20
   PubMedGoogle Scholar
• Gutai J, La Porte R, Kuller L. Plasma testosterone, high density lipoprotein cholesterol and other lipoprotein fraction. Am J Cardiol 1981; 48: 897–902
   PubMed Web of Science ®Google Scholar
• Freedman D S, O'Brien T R, Flanders WD. Relation of serum testosterone levels to high density lipoprotein cholesterol and other characteristics in men. Arterioscler Thromb 1991; 11: 307–15
   PubMedGoogle Scholar
• Simon D, Charles M A, Nahoul K. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men. J Clin Endocrinol Metab 1997; 82: 682–5
   PubMed Web of Science ®Google Scholar
• Phillips G B, Pinkernell B H, Jing T. The association of hypotestosteronemia with coronary artery disease. Arterioscler Thromb 1994; 14: 701–6
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw K, Yen S SC. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986; 315: 1519–24
   PubMed Web of Science ®Google Scholar
• Slowiniska-Srzednicka Zglizyniski S, Cicewicka-Sznajderman M, Srzednicki M. Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 1989; 79: 197
   PubMedGoogle Scholar
• Breier C. h., Drexel H, Lisch HJ. Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease. Lancet 1985; 1: 1242–4
   PubMedGoogle Scholar
• Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996; 125: 1–13
   PubMed Web of Science ®Google Scholar
• Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, Brzezinska A, Zgliczynski W. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 1996; 121: 35–43
   PubMed Web of Science ®Google Scholar
• Raichlen J S, Healy B, Stephen C, Achuff C, Thomas A. Importance of risk factors in angiographic progression of coronary artery disease. Am J Cardiol 1986; 57: 66–70
   PubMedGoogle Scholar
• Marwick T, D'Hondt A, Baudhuin T, Willemart B, Wijns W. Optimal use of Dobutamine stress for the detection and evaluation of coronary artery disease: combination with echocardiography or scintigraphy, or both. J Am Coll Cardiol 1993; 22: 159–67
   PubMed Web of Science ®Google Scholar
• LaCroix A Z, Katsuhiko Y, Reed DM. Dehydroepiandrostcrone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992; 86: 1529
   PubMed Web of Science ®Google Scholar
• Kask E. 17-Ketosteroids and arteriosclerosis. Angiology 1959; 10: 358–68
   PubMedGoogle Scholar
• Herrington D M, Gordon G B, Achuff SC. Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990; 16: 862–70
   PubMedGoogle Scholar
• Hautanen A, Manttari M, Mannnimen M. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994; 105: 191–200
   PubMed Web of Science ®Google Scholar
• Nafziger A N, Herrington D M, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev 1991; 13: 267–93
   PubMed Web of Science ®Google Scholar
• Ben-David M, Dikstein S, Bismuth G. Antihypercholesterolemic effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 1967; 125: 1136–40
   PubMedGoogle Scholar
• Kurzman I D, Macewen E G, Haffa AL. Reduction in body weight and cholesterol in spontaneously obese dogs by dehydroepiandrosterone. Int J Obes 1990; 14: 95–104
   PubMed Web of Science ®Google Scholar
• Eich D M, Nestler J E, Johnson DE. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic. Circulation 1993; 87: 261–9
   PubMed Web of Science ®Google Scholar
• Berdanier C D, Parente J A, McIntosh MK. Is dehydroepiandrosterone an antiobesity agent?. FASEB J 1993; 7: 414–19
   PubMedGoogle Scholar
• Nestler J E, Barlascini C O, Clore JN. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988; 66: 57–61
   PubMed Web of Science ®Google Scholar
• Nestler J E, Clore J N, Blackard WG. Dehydroepiandrosterone: the ‘missing link’ between hyperinsulinemia and atherosclerosis?. FASEB J 1992; 6: 3073–5
   PubMedGoogle Scholar
• Philips GB. Relationship between serum dehydroepiandrosterone sulfate, androstenedione, and sex hormones in men and women. Eur J Endocrinol 1996; 134: 201–6
   PubMedGoogle Scholar
• Sewdarsen M, Vythilingum S, Jialal I, Desai R K, Becker P. Abnormalities in sex hormones are a risk factor for premature manifestation of coronary artery disease in South African Indian men. Atherosclerosis 1990; 83: 111
   PubMedGoogle Scholar
• Marques-Vidal P, Sie P, Cambou J, Chap H, Perret B. Relationship of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17beta estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab 1995; 80: 1794–8
   PubMedGoogle Scholar
• Anderson R A, Wallace E M, Wu W. Effect of testosterone enanthate on serum lipoproteins in men. Contraception 1995; 52: 115–19
   PubMed Web of Science ®Google Scholar
• Marcovina S M, Lippi G, Bagatell C J, Bremner WJ. Testosterone-induced suppression of lipoprotein (a) in normal men; relation to basal lipoprotein (a) level. Atherosclerosis 1996; 122: 89–95
   PubMed Web of Science ®Google Scholar
• Ozata M, Yildrimkaya M, Bulur M, Yilmaz K, Bolu E, Corakci A. Effects of gonadotropin and testosterone treatments on lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism. J Clin Endocrinol Metab 1996; 81: 3372–8
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E L. Testosterone and risk factors for cardiovascular disease in men. Diabet Metab 1995; 21: 156–61
   Google Scholar
• Morley J E, Perry H M, Kaiser F E, Jensen J, Houston K. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52
   PubMed Web of Science ®Google Scholar
• Hoefler G, Harnoncourt F, Paschke E. Lipoprotein Lp(a) a risk factor for myocardial infarction. Arteriosclerosis 1988; 8: 398–401
   PubMedGoogle Scholar
• Howard G C, Pizzo SV. Biology of disease. Lipoprotein(a) and its role in atherothrombotic disease. Lab Invest 1993; 69: 373–85
   PubMed Web of Science ®Google Scholar
• Duerr R L, Ross RS. Acute myocardial infarction in a young man. Are there any risk factors?. Trends Cardiovasc Med 1993; 3: 44–7
   PubMedGoogle Scholar
• Bartens W, Wanner C. Lipoprotein(a): new insights into an atherogenic lipoprotein. Clin Invest 1994; 72: 558–67
   PubMedGoogle Scholar
• Scanu A M. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. J Am Med Assoc 1992; 267: 3326–9
   PubMed Web of Science ®Google Scholar
• Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672–9
   PubMedGoogle Scholar
• Armstrong V W, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986; 62: 249–57
   PubMed Web of Science ®Google Scholar
• Dahlen G H, Guyton J R, Attar M, Farmer J. Association of levels of lipoprotein(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758–65
   PubMed Web of Science ®Google Scholar
• Lobo R A, Notelovitz M, Bernstein L, Khan F Y, Ross RK. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 1992; 166: 1182–90
   PubMed Web of Science ®Google Scholar
• Berglund L, Carlstrom K, Stege R, Gottlieb C, Eriksson M. Hormonal regulation of serum lipoprotein(a) levels: effects of parenteral administration of estrogen or testosterone in males. J Clin Endocrinol Metab 1996; 81: 2633–7
   PubMed Web of Science ®Google Scholar
• Lobo R. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991; 73: 925–30
   PubMed Web of Science ®Google Scholar
• Soma M R, Osnago-Gadda I, Paoletti R, Fumagalli R. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993; 153: 1462–8
   PubMed Web of Science ®Google Scholar
• Soma M, Meschia M, Ghenem K. Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991; 337: 612
   PubMed Web of Science ®Google Scholar
• Taskinen M R, Puolakka J, Pyorala T. Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen–progestin regimes. Arterioscler Thromb Vasc Biol 1996; 16: 1215–21
   PubMed Web of Science ®Google Scholar
• Mendoza S G, Zerpa A, Velazquez E, Schwarzenberg A, Hynd B, Kashyp M L, et al. Sex hormones, lipids, lipoprotein cholesterols, and apolipoproteins in normal and obese subjects: atherogenic relationships. Int J Obes 1986; 10: 427–41
   PubMedGoogle Scholar
• Khaw K, Barrett-Connor E. Low endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675–82
   PubMedGoogle Scholar
• Barrett-Connor E, Khaw K. Endogenous sex hormones and cardiovascular disease in men. Circulation 1988; 78: 539–45
   PubMed Web of Science ®Google Scholar
• Simon D, Preziosi P, Barrett-Connor E, Roger M, Nahoul K, Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telcom Study. Diabetologia 1992; 35: 173–7
   PubMed Web of Science ®Google Scholar
• Deutscher S, Bates M W, Caines M J, LaPorte R E, Punterei A. Relationship between serum testosterone, fasting insulin and lipoprotein levels among elderly men. Atherosclerosis 1989; 75: 13–22
   PubMedGoogle Scholar
• Haffner S M, Shaten J, Stem M P, Smith G D, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulindependent diabetes mellitus in men. Am J Epidemiol 1996; 143: 889–97
   PubMed Web of Science ®Google Scholar
• Jeppesen L L, Jorgensen H S, Nakayama H. Decreased serum testosterone in men with acute ischemic stroke. Arterioscler Thromb Vasc Biol 1996; 16: 749–54
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Khaw K T, Yen S SC. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990; 132: 895–901
   PubMed Web of Science ®Google Scholar
• Glueck C J, Glueck H I, Stroop D. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 1993; 122: 412–20
   PubMed Web of Science ®Google Scholar
• Caron P, Bennet A, Camare JP. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38: 1010–15
   PubMed Web of Science ®Google Scholar
• Bonithon-Kopp C, Scarabin P Y, Bara L. Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 1988; 71: 71–6
   PubMed Web of Science ®Google Scholar
• Heller R F, Meade T W, Haines AP. Interrelationships between factor VII, serum testosterone and plasma lipoproteins. Thromb Res 1982; 28: 423–5
   PubMedGoogle Scholar
• Chou T M, Sudhir K, Hutchison SJ. Testosterone induces dilatation of canine coronary conductance and resistance arteries in vivo. Circulation 1996; 94: 2614–19
   PubMed Web of Science ®Google Scholar